Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients

NCT04998604 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04998604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
September 27, 2021
Completion date
December 27, 2024
Enrollment
360 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic rhinosinusitis with nasal polyps